Methotrexate: CirtIfied for Preventing Atherosclerotic Events?
- 1 June 2019
- journal article
- research article
- Published by SAGE Publications in Journal of the Royal College of Physicians of Edinburgh
- Vol. 49 (2) , 136-138
Abstract
Title Low-dose methotrexate for the prevention of atherosclerotic events Authors Ridker PM, Everett BM, Pradhan A et al.; CIRT Investigators Journal N Engl J Med 2019; 21: 380: 752–62.Keywords
This publication has 10 references indexed in Scilit:
- Low-Dose Methotrexate for the Prevention of Atherosclerotic EventsNew England Journal of Medicine, 2019
- Cantos - is Selective Targeting of Inflammation in Atherosclerosis Enough?Journal of the Royal College of Physicians of Edinburgh, 2018
- Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)European Heart Journal, 2018
- Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trialThe Lancet, 2018
- Inflammation in AtherosclerosisJACC, 2009
- The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature reviewRheumatology, 2009
- Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA studyArthritis Research & Therapy, 2008
- Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritisJournal of the American Academy of Dermatology, 2005
- Methotrexate and mortality in patients with rheumatoid arthritis: a prospective studyThe Lancet, 2002
- Molecular action of methotrexate in inflammatory diseasesArthritis Research & Therapy, 2002